🍪 CompoundTalk uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsSemaglutide (Ozempic / Wegovy)Weekly injection day thread — my results so far

Weekly injection day thread — my results so far

RetaRick_CA Mon, Jan 20, 2025 at 6:24 PM 30 replies 1,920 viewsPage 1 of 6
This thread is more than 16 months old. Information may be outdated. Consider searching for more recent discussions.
RetaRick_CA
VIP Member
2,012
9,876
Jan 2024
California
Jan 20, 2025 at 6:24 PM#1

This gets cited here weekly, usually second-hand, so it is worth setting out what it does and does not establish.

Steady state is the thing most people miss. The terminal half-life is about a week, so every dose step takes four to five weeks to fully express itself. Judging a step at day ten is judging the ascent, not the plateau, and it is the single commonest reason people escalate before they needed to.

Where I think it is weakest: the subgroup findings are the part I trust least — with enough subgroups something is always significant, and these were not all pre-registered.

What I am trying to establish is how much of the between-person variation is pharmacokinetic and how much is just adherence measured badly. I would rather have one careful answer than five confident ones.

Note on sourcing:
Figures above are from the primary publication rather than the press summary. If a number here disagrees with one you have, post yours and we will work out which of us is reading a secondary source.
38 8SkepticalSean, Dr.CardioMD, EndoResFellow and 35 others
Reply Quote Save Share Report
Dr.CardioMD
VIP Member
2,678
14,567
Dec 2023
Cleveland, OH
Jan 20, 2025 at 6:32 PM#2
RetaRick_CA said:
Steady state is the thing most people miss.

All true, with one condition: that curve is for people who reached the dose on schedule. Anyone who slowed the ladder for tolerability is on a different, flatter curve, and comparing yourself with the published mean will make you feel like a non-responder when you are not.

37 7Dr.NephBHM_UK, kim_atl_prep, sarah_TO and 34 others
Reply Quote Save Share Report
NeuroNate
Senior Member
2,890
16,789
Dec 2023
Chicago, IL
Jan 20, 2025 at 6:40 PM#3
RetaRick_CA said:
Steady state is the thing most people miss.

I will push back on the "any working dose is fine" framing. The maintenance evidence sits overwhelmingly at the top studied dose, and the extension data shows regain tracking dose reduction rather than tracking stopping. Holding low is reasonable; pretending it is evidentially equivalent is not.

36 6sarah_TO, wendy_avl, jason_paloalto and 33 others
Reply Quote Save Share Report

Sigma-Aldrich — Research-Grade Standards

Certified reference materials, analytical reagents, and research-grade standards for peptide verification. Trusted by laboratories worldwide.

Shop Reference Standards
SarahChen_PharmD
VIP Member
4,567
22,341
Dec 2023
San Diego, CA
Jan 20, 2025 at 6:48 PM#4

This one has a reasonably settled answer, so here it is. The mechanism that matters here is not stomach emptying, it is central. GLP-1 receptor agonism in the arcuate nucleus stimulates POMC neurons and suppresses AgRP/NPY signalling, which is why the effect is appetite and food salience rather than physical fullness. Delayed gastric emptying largely tachyphylaxes over the first months; the appetite effect does not.

Last edited: Jan 20, 2025 at 9:48 PM
35 5TinaHashiRN, robert_kc, dan_philly and 32 others
Reply Quote Save Share Report
hans_munich
Member
534
2,345
Jul 2024
Munich, DE
Jan 20, 2025 at 7:30 PM#5
Dr.CardioMD said:
All true, with one condition: that curve is for people who reached the dose on schedule.

That holds for the injectable. The oral formulation has different absorption behaviour and the dose numbers are not interchangeable, which is worth saying out loud because people quote them as if they were.

If somebody has the primary source to hand I would rather cite it than paraphrase it.

34 4emma_london, tammy_FL, Dr.LipidDallas and 31 others
Reply Quote Save Share Report
1236

Similar Threads

STEP 1-5 trials comprehensive summary — efficacy endpoints compiled12 replies
Oral semaglutide 50mg Phase 3 — OASIS program results16 replies
Semaglutide pharmacokinetics — half-life, Tmax, steady state modeling10 replies
Compounded semaglutide stability data — temperature and light sensitivity16 replies
0.25mg → 2.4mg titration: optimal schedule based on clinical data6 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register